<DOC>
	<DOCNO>NCT00782106</DOCNO>
	<brief_summary>The purpose study determine feasibility infuse full 4-week dose Immune Globulin Intravenous ( Human ) , 10 % single subcutaneous site amount recombinant human hyaluronidase need infuse dose mild local adverse drug reaction .</brief_summary>
	<brief_title>Study Determine Dose Recombinant Human Hyaluronidase Needed Infuse Full Dose IGIV Subcutaneously</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Written inform consent either subject subject 's legally acceptable representative Diagnosis PID disorder define World Health Organization criteria1 subject receive regimen weekly biweekly ( everyotherweek ) subcutaneous IgG infusion IGIV infusion every 21 28 day period least 8 week prestudy equivalent 4week dose 300 800 mg/kg bodyweight Adults/adolescents age 16 year old ) For female subject childbearing age : negative urine pregnancy test result study entry agreement employ adequate birth control measure duration study Subjects positive enrollment one following : HBsAg , PCR HCV , PCR HIV Type 1 Subjects level alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 time upper limit normal test laboratory Subjects neutropenia ( define absolute neutrophil count [ ANC ] &lt; = 500/mm3 ) . Subjects serum creatinine level great 1.5 time upper limit normal age gender Subjects current history malignancy Subjects history thrombotic episode ( deep vein thrombosis , myocardial infarction , cerebrovascular accident ) Subjects abnormal protein loss ( protein lose enteropathy , nephritic syndrome , severe lung disease ) Subjects anemia opinion investigator preclude phlebotomy laboratory study Subjects expose blood blood product intravenous immunoglobulin ( IGIV ) , SC immunoglobulin ( SCIG ) , immune serum globulin ( ISG ) preparation , albumin within 6 month prior study entry . Subjects ongoing history hypersensitivity persistent reaction ( urticaria , breathe difficulty , severe hypotension , anaphylaxis ) follow IGIV , SCIG and/or ISG infusion Subjects IgA deficiency know anti IgA antibody Subjects receive antibiotic therapy treatment infection within 7 day prior enrollment Subjects participate another clinical study involve investigational product device within 28 day prior study entry Subjects inability unwillingness meet requirement study If female , pregnancy lactation time study entry</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>